Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis
Status:
Unknown status
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of rituximab when added to NSAIDs and/ or methotrexate
both for TNFalpha inhibitor naïve or TNFalpha inhibitor failure patients with moderate to
severe ankylosing spondylitis